ACADIA Pharmaceuticals Inc

Latest ACADIA Pharmaceuticals Inc News and Updates

  • uploads///Part  Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals Initiates Phase 1 Trial of ALN-TTRsc02

    Alnylam Pharmaceuticals (ALNY) was one of the most underperforming biotech stocks for the week ended June 10, 2016. It fell 10% due to profit booking.

    By Peter Neil
  • uploads///AdobeStock_
    Company & Industry Overviews

    Why Is Acadia Pharmaceuticals Falling Today?

    Yesterday, Acadia Pharmaceuticals reported top-line results from its phase three trial evaluating Nuplazid in schizophrenia.

    By Margaret Patrick
  • uploads///Spectrum net loss
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.

    By Daniel Collins
  • uploads///Spectrum
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Financial Overview in December

    In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.

    By Daniel Collins
  • uploads///lab _
    Company & Industry Overviews

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.

    By Daniel Collins
  • uploads///ACAD
    Company & Industry Overviews

    Exploring Acadia Pharmaceuticals’ Promising Research Pipeline

    Acadia Pharmaceuticals’ Nuplazid is commercialized in the US market for the treatment of hallucinations and delusions related to Parkinson’s disease psychosis.

    By Kenneth Smith
  • uploads///Fei
    Company & Industry Overviews

    Why Axovant Sciences Stock Rose in Week Ended June 8

    On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Nuplazid for Long-Term Care: Revenue Driver for Acadia?

    Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Nuplazid Sees Increasing Physician Intent to Prescribe in 2017

    Acadia Pharmaceuticals’ (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Nuplazid Expected to Become a Leading Central Nervous System Drug

    On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Acadia Pharmaceuticals in September

    Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue

    Analyst estimates show Ionis Pharmaceuticals’ 2016 revenue at $237 million. That’s a decline of more than 16% compared to $284 million for 2015.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva

    Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Incyte Continues Its Growth Spree in 2015

    Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Mid-Cap News: Look Who Took a Beating on March 23

    Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Dyax Traded above Its 100-Day Moving Average

    Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Anacor Pharmaceuticals Outperforms the Market

    Within IBB, stocks like Receptos and Celgene performed well. However, Anacor Pharmaceuticals outperformed everyone with an eye-catching 71.92% for the week ending July 17.

    By Peter Neil
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.